Gracell Biotechnologies Statistics
Share Statistics
Gracell Biotechnologies has 96.57M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 96.57M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 145,000 |
| FTD / Avg. Volume | 9.9% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.81 and the forward
PE ratio is null.
Gracell Biotechnologies's PEG ratio is
0.14.
| PE Ratio | -2.81 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 1.24 |
| P/FCF Ratio | -3.21 |
| PEG Ratio | 0.14 |
Financial Ratio HistoryEnterprise Valuation
Gracell Biotechnologies has an Enterprise Value (EV) of 433.44M.
| EV / Sales | 0 |
| EV / EBITDA | -0.73 |
| EV / EBIT | -0.9 |
| EV / FCF | -0.82 |
Financial Position
The company has a current ratio of 6.78,
with a Debt / Equity ratio of 0.13.
| Current Ratio | 6.78 |
| Quick Ratio | 6.9 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | -0.31 |
| Debt / FCF | -0.05 |
| Interest Coverage | -92.72 |
Financial Efficiency
Return on Equity is -44.16% and Return on Invested Capital is -40.08%.
| Return on Equity | -44.16% |
| Return on Assets | -36.68% |
| Return on Invested Capital | -40.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,934,742.04 |
| Employee Count | 314 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 22K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is -0.34, so Gracell Biotechnologies's
price volatility has been lower than the market average.
| Beta | -0.34 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 9.23 |
| 200-Day Moving Average | 5.05 |
| Relative Strength Index (RSI) | 68.18 |
| Average Volume (20 Days) | 1,464,475 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -624.66M |
| Net Income | -607.51M |
| EBITDA | -592.58M |
| EBIT | -600.75M |
| Earnings Per Share (EPS) | -5.65 |
Full Income StatementBalance Sheet
The company has 1.45B in cash and 182.98M in
debt, giving a net cash position of 1.27B.
| Cash & Cash Equivalents | 1.45B |
| Total Debt | 182.98M |
| Net Cash | 1.27B |
| Retained Earnings | -1.63B |
| Total Assets | 1.89B |
| Working Capital | 1.54B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -3.31B
and capital expenditures -331.55M, giving a free cash flow of -3.64B.
| Operating Cash Flow | -3.31B |
| Capital Expenditures | -331.55M |
| Free Cash Flow | -3.64B |
| FCF Per Share | -4.94 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
